Experimental drug lowers serum phosphate in phase 3 trial of hemodialysis patients

In a phase 3 clinical trial, tenapanor significantly lowered elevated blood phosphate in patients receiving maintenance hemodialysis, resulting in an average reduction of 1.0-1.2 mg/dL over eight weeks. Side effects were largely limited to softening of stool and more frequent bowel movements.

from Top Health News -- ScienceDaily https://ift.tt/2STGNPZ